Refine
Year of publication
Language
- English (31)
Has Fulltext
- yes (31)
Is part of the Bibliography
- no (31)
Keywords
- Multiple sclerosis (2)
- Neuroinflammation (2)
- ceramides (2)
- inflammation (2)
- macrophage (2)
- pain (2)
- sphingolipids (2)
- sphingosine kinase (2)
- stroke (2)
- A498 cells (1)
- AMP-activated kinase (1)
- Acquired resistance (1)
- Acute lymphoblastic leukemia (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Autoimmune encephalomyelitis (1)
- Biomarkers (1)
- Brain injury (1)
- CNDAC (1)
- CTGF (1)
- CYP1A1 (1)
- Cancer (1)
- DCK (1)
- DNA damage (1)
- Diagnostic markers (1)
- Entorhinal cortex lesion (1)
- FTY720 (1)
- G-protein-coupled receptors (1)
- G2A (1)
- GEMs (1)
- GPCR (1)
- Glycolysis (1)
- Gαq/11 (1)
- HCC marker (1)
- HIV (1)
- HIV-1 (1)
- IFN-β (1)
- Intrinsic resistance (1)
- Leukemia (1)
- Lipid signaling (1)
- Lpar2 (1)
- Lysophosphatidic acids (1)
- MLV (1)
- MRP4 (1)
- Mitochondrial ROS (1)
- Nociception (1)
- Oncology (1)
- Oxidative phosphorylation (1)
- PKA (1)
- PRG-1 (1)
- RCC (1)
- S1P receptors (1)
- SAMHD1 (1)
- SAMHD1 knockout mouse (1)
- SAMHD1 phosphorylation (1)
- Sapacitabine (1)
- Spinal cord (1)
- Structural plasticity (1)
- T-cell homing (1)
- acute inflammation (1)
- adenosine receptors (1)
- analgesia (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- beta blockade (1)
- bioactive lipids (1)
- bioactive phospholipids (1)
- biomarker (1)
- blood pressure (1)
- breast cancer (1)
- cAMP (1)
- caloric restriction (1)
- cannabinoid receptor type 1 (1)
- cortical network (1)
- data science (1)
- dendritic cells (1)
- eNPP2 (1)
- endocannabinoids (1)
- epigenetics (1)
- exercise (1)
- fibrosarcoma (1)
- glucose metabolism (1)
- graft rejection (1)
- hepatitis C (1)
- histone deacetylase (1)
- human pain models (1)
- human pharmacology (1)
- hyperglycemia (1)
- ischemic type biliary lesions (1)
- mast cells (1)
- microlesions (1)
- migration (1)
- multiple sclerosis (1)
- orthopic liver transplantation (1)
- perineurium (1)
- polarization (1)
- post-exercise hypotension (1)
- prostaglandin E (1)
- prostaglandins (1)
- psychiatric disorders (1)
- regulatory T helper cells (1)
- resolution (1)
- sciatic nerve (1)
- smooth muscle cells (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine 1-phosphate homologues (1)
- sphingosine 1-phosphate receptor (1)
- sphingosine-1-phosphate (1)
- synapse (1)
- toll-like receptor (1)
- tumor pain (1)
- vascular biology (1)
- xenobiotics (1)
- fingolimod (1)
Institute
- Medizin (29)
- Zentrum für Arzneimittelforschung, Entwicklung und Sicherheit (ZAFES) (6)
- Biochemie, Chemie und Pharmazie (2)
- Biowissenschaften (2)
- Pharmazie (2)
- Sonderforschungsbereiche / Forschungskollegs (2)
- Institut für Ökologie, Evolution und Diversität (1)
- Interdisziplinäres Zentrum für Neurowissenschaften Frankfurt (IZNF) (1)
- Senckenbergische Naturforschende Gesellschaft (1)
Sphingosine 1-phosphate (S1P) is a lipid mediator with numerous biological functions. The term ‘S1P’ mainly refers to the sphingolipid molecule with a long-chain sphingoid base of 18 carbon atoms, d18:1 S1P. The enzyme serine palmitoyltransferase catalyses the first step of the sphingolipid de novo synthesis using palmitoyl-CoA as the main substrate. After further reaction steps, d18:1 S1P is generated. However, also stearyl-CoA or myristoyl-CoA can be utilised by the serine palmitoyltransferase, which at the end of the S1P synthesis pathway, results in the production of d20:1 S1P and d16:1 S1P respectively. We measured these S1P homologues in mice and renal tissue of patients suffering from renal cell carcinoma (RCC). Our experiments highlight the relevance of d16:1 S1P for the induction of connective tissue growth factor (CTGF) in the human renal clear cell carcinoma cell line A498 and human RCC tissue. We show that d16:1 S1P versus d18:1 and d20:1 S1P leads to the highest CTGF induction in A498 cells via S1P2 signalling and that both d16:1 S1P and CTGF levels are elevated in RCC compared to adjacent healthy tissue. Our data indicate that d16:1 S1P modulates conventional S1P signalling by acting as a more potent agonist at the S1P2 receptor than d18:1 S1P. We suggest that elevated plasma levels of d16:1 S1P might play a pro-carcinogenic role in the development of RCC via CTGF induction.
Epigenetic control of microsomal prostaglandin E synthase-1 by HDAC-mediated recruitment of p300
(2017)
Nonsteroidal anti-inflammatory drugs are the most widely used medicine to treat pain and inflammation, and to inhibit platelet function. Understanding the expression regulation of enzymes of the prostanoid pathway is of great medical relevance. Histone acetylation crucially controls gene expression. We set out to identify the impact of histone deacetylases (HDACs) on the generation of prostanoids and examine the consequences on vascular function. HDAC inhibition (HDACi) with the pan-HDAC inhibitor, vorinostat, attenuated prostaglandin (PG)E2 generation in the murine vasculature and in human vascular smooth muscle cells. In line with this, the expression of the key enzyme for PGE2 synthesis, microsomal PGE synthase-1 (PTGES1), was reduced by HDACi. Accordingly, the relaxation to arachidonic acid was decreased after ex vivo incubation of murine vessels with HDACi. To identify the underlying mechanism, chromatin immunoprecipitation (ChIP) and ChIP-sequencing analysis were performed. These results suggest that HDACs are involved in the recruitment of the transcriptional activator p300 to the PTGES1 gene and that HDACi prevented this effect. In line with the acetyltransferase activity of p300, H3K27 acetylation was reduced after HDACi and resulted in the formation of heterochromatin in the PTGES1 gene. In conclusion, HDAC activity maintains PTGES1 expression by recruiting p300 to its gene.
Identifying co-expression of lipid species is challenging, but indispensable to identify novel therapeutic targets for breast cancer treatment. Lipid metabolism is often dysregulated in cancer cells, and changes in lipid metabolism affect cellular processes such as proliferation, autophagy, and tumor development. In addition to mRNA analysis of sphingolipid metabolizing enzymes, we performed liquid chromatography time-of-flight mass spectrometry analysis in three breast cancer cell lines. These breast cancer cell lines differ in estrogen receptor and G-protein coupled estrogen receptor 1 status. Our data show that sphingolipids and non-sphingolipids are strongly increased in SKBr3 cells. SKBr3 cells are estrogen receptor negative and G-protein coupled estrogen receptor 1 positive. Treatment with G15, a G-protein coupled estrogen receptor 1 antagonist, abolishes the effect of increased sphingolipid and non-sphingolipid levels in SKBr3 cells. In particular, ether lipids are expressed at much higher levels in cancer compared to normal cells and are strongly increased in SKBr3 cells. Our analysis reveals that this is accompanied by increased sphingolipid levels such as ceramide, sphingadiene-ceramide and sphingomyelin. This shows the importance of focusing on more than one lipid class when investigating molecular mechanisms in breast cancer cells. Our analysis allows unbiased screening for different lipid classes leading to identification of co-expression patterns of lipids in the context of breast cancer. Co-expression of different lipid classes could influence tumorigenic potential of breast cancer cells. Identification of co-regulated lipid species is important to achieve improved breast cancer treatment outcome.